Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Is the GAIN Act a turning point in new antibiotic discovery?

Brown ED.

Can J Microbiol. 2013 Mar;59(3):153-6. doi: 10.1139/cjm-2013-0089. Epub 2013 Feb 6.

2.

Antibiotic bill doesn't GAIN enough ground.

Ambrose PG.

Nat Med. 2011 Jul 7;17(7):772. doi: 10.1038/nm0711-772.

PMID:
21738147
3.

Re-engineering drug discovery and development.

FitzGerald GA.

LDI Issue Brief. 2011 Oct;17(2):1-4.

PMID:
22049582
4.

Forging a new path. New law offers incentives to develop antibiotics.

Lee J.

Mod Healthc. 2013 Feb 4;43(5):8-9. No abstract available.

PMID:
23437480
5.

Incentives aim to boost antibiotic development.

Roberts JP.

Nat Biotechnol. 2012 Aug;30(8):735. doi: 10.1038/nbt0812-735a. No abstract available.

PMID:
22871701
6.

Raising the bar for market authorisation of new drugs.

Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K.

BMJ. 2012 Aug 7;345:e4261. doi: 10.1136/bmj.e4261. No abstract available.

PMID:
22872693
8.

Improving antibiotic markets for long-term sustainability.

Kesselheim AS, Outterson K.

Yale J Health Policy Law Ethics. 2011 Winter;11(1):101-67. No abstract available.

PMID:
21381513
9.

Using market-exclusivity incentives to promote pharmaceutical innovation.

Kesselheim AS.

N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961. No abstract available.

10.

GAIN Act legislation: is it enough?

Tillotson GS.

Lancet Infect Dis. 2012 Nov;12(11):823-4. doi: 10.1016/S1473-3099(12)70260-8. No abstract available.

PMID:
23099071
11.

A precarious balancing act--the role of the FDA as protector of public health and industry wealth.

McCabe AR.

Suffolk Univ Law Rev. 2003;36(3):787-819. No abstract available.

PMID:
16493844
12.

Industry and regulatory performance in 2012: a year in review.

Dowden HM, Jahn R, Catka T, Jonsson A, Michael E, Miwa Y, Zinkand W.

Clin Pharmacol Ther. 2013 Sep;94(3):359-66. doi: 10.1038/clpt.2013.91. Epub 2013 May 8. Review.

PMID:
23657160
13.

Drug development: Time for teamwork.

May M.

Nature. 2014 May 1;509(7498):S4-5. doi: 10.1038/509S4a. No abstract available.

PMID:
24784427
14.

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Spellberg B, Sharma P, Rex JH.

Nat Rev Drug Discov. 2012 Feb 1;11(2):168. doi: 10.1038/nrd3560-c1. No abstract available.

15.

A three-step plan for antibiotics.

[No authors listed]

Nature. 2014 May 29;509(7502):533. No abstract available.

PMID:
24877183
16.

A cheat sheet to navigate the complex maze of exclusivities in the United States.

Peng B, Tomas MC.

Pharm Pat Anal. 2014 Jul;3(4):339-43. doi: 10.4155/ppa.14.30. No abstract available.

17.

Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.

Spellberg B, Miller LG, Kuo MN, Bradley J, Scheld WM, Edwards JE Jr.

Infection. 2007 Jun;35(3):167-74.

PMID:
17565458
18.

[Does the public sector have an independent research role in the development of drugs?].

Poulsen HE, Grønlykke TB.

Ugeskr Laeger. 2003 Apr 14;165(16):1674-6. Danish.

PMID:
12756828
19.

Stimulating antibiotic development.

Tillotson G.

Lancet Infect Dis. 2010 Jan;10(1):2-3. doi: 10.1016/S1473-3099(09)70333-0. No abstract available.

PMID:
20129141
20.

Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.

Kaitin KI, DiMasi JA.

Clin Pharmacol Ther. 2011 Feb;89(2):183-8. doi: 10.1038/clpt.2010.286. Epub 2010 Dec 29. Review.

PMID:
21191382

Supplemental Content

Support Center